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Introduction: Primary lung clear cell adenocarcinomas represent a very rare histologic type.
Little is known about their molecular and clinical features.
Presentation of the case: An asymptomatic 59-year-old female smoker was incidentally
diagnosed with a solitary peripheral pulmonary nodule without evidence of lymphadenopathy.
The patient underwent a surgical resection. The poorly differentiated adenocarcinoma
consisted almost entirely of clear cells (pT1a, G3, R0, pN2, cM0, stage IIIA). Other primary
tumors were excluded by immunohistochemistry. Molecular analyses revealed the G12D
mutation in the KRAS gene. No EGFR mutation or EML4/ALK fusion gene was present.
Discussion: Clear cell features are sometimes observed in various histologic types of lung cancer.
Adenocarcinomas entirely comprised of clear cells are very rare. Here we describe a putative driver
mutation in a case of lung clear cell adenocarcinoma.
Conclusion: This is the ﬁrst description of molecular aberrations in a clear cell adenocarcinoma of
the lung.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Lungs tumors frequently show clear cell histology [1]. The clear
appearance results from intracellular accumulation of glycogen
in absence of mucus production [2]. Most clear cell tumors areThe Authors. Published by Elsevi
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sz.ch (A. Curioni-Fontecedro).metastases of, e.g., renal or ovarian tumors. Clear cell
histology does also occur in primary lung cancers, most often
in benign “sugar cell” tumors. Carcinomas entirely composed of
clear cells are very rare, especially adenocarcinomas. We here
present a case of locally advanced clear cell adenocarcinoma
and its molecular characteristics.2. Presentation of case
A 59-year-old woman was incidentally diagnosed with a
solitary pulmonary nodule. The patient was asymptomatic
except for chronic cough. Her past medical history waser Ltd. All rights reserved.
Fig. 3 Lymph node contains clear cells that stain positive for
pan-cytokeratin in IHC. Bar: 100 mm.
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stage II and for coronary artery disease. The patient was an
active smoker with a 30-pack-year history. She had no
family history of neoplastic disease and no occupational
carcinogen exposure. Computed tomography of the chest
conﬁrmed the presence of a 13 9 11 mm3 nodule in the
apical upper lobe of the left lung. For staging, a ﬂuoro-
deoxyglucose positron-emission tomography (PET-CT) was
performed. The nodule showed low metabolic activity. No
lymph node or distant metastases were detected. The
patient underwent a three-segment resection by thoracot-
omy with radical mediastinal lymphadenectomy.
Histologically, a poorly differentiated clear cell adenocarci-
noma with predominantly solid growth pattern, central necrosis
and very scarce marginal lepidic non-mucinous growth was
diagnosed. The tumor was entirely composed of clear cells with
cytosolic granules positive for periodic acid–Schiff (PAS), which
disappeared after digestion with diastase. In the alcian-blue
periodic acid–Schiff (AB-PAS) stain, light-blue cytosolic vacuoles
were found. No lymphatic or blood vessel invasion was present.
One out of 14 lymph nodes (left subaortic) showed a 2.5 mm
macrometastasis consisting entirely of clear cells.
By immunohistochemistry (IHC), the tumor was strongly
positive for pan-cytokeratin, CK7 as well as TTF1 and
negative for CK20, RCC, CD10, CK5/6, S100 and HMB45.
Sequencing of exons 18–21 of the EGFR gene demonstrated
no mutations associated with geﬁtinib or erlotinib sensitiv-
ity. Sequencing of KRAS exons 2–4 revealed the pointFig. 1 Lung tumor was entirely composed of solid sheets of
clear cells with scarce lepidic margins. Staining, hematoxylin–
eosin. Bar: 200 mm.
Fig. 2 IHC shows nuclear staining for TTF-1. Bar: 100 mm.mutation G12D. Fluorescence in-situ hybridization analysis
detected no translocation of the ALK gene (2p23).
The pathological diagnosis was pure clear cell adenocar-
cinoma of the lung, grade G3, stage pT1a pN2 R0 cM0 (IIIA).
The patient underwent adjuvant chemotherapy with
cisplatin and pemetrexed for a total of four cycles. Nine
months after the operation, the patient did not have any
clinical or radiological evidence of recurrence Figs. 1–3.
3. Discussion
Clear cell carcinomas (CCC) of the lung can either be a
histologic variant of adenocarcinomas or of large cell carcino-
mas as per current WHO guidelines [3]. There is, however,
consensus that they should not be considered as an own entity
but rather a subtype of the main histotypes [1,2,4]. As this
tumor showed a marginal lepidic outgrowth and AB-PAS positive
mucin vacuoles, we classiﬁed it as variant of adenocarcinoma.
Metastases of, e.g., clear cell renal cell carcinoma (ccRCC) and
primary lung “sugar cell” tumors have to be considered in
differential diagnosis. The latter are not of epithelial origin and
are generally considered benign [2].
Adenocarcinomas occasionally show features of clear cells,
especially when poorly differentiated [2]. Pure clear cell
adenocarcinomas of the lungs are very rare. Only three cases
of clear cell adenocarcinomas of the lungs with conﬁrmation by
immunohistochemistry have been reported [5–7].
CCCs occur in several tissues; clear cell tumors of the ovary,
endometrium and kidney are associated with a worse prognosis
than other major subtypes [8,9]. The clinical and prognostic
implications of clear cell change in lung tumors are unclear.
Despite high similarities in gene expression between CCCs
of the kidney, ovary and endometrium [8], no mutual driver
mutation has been identiﬁed. KRAS mutations are common
in clear cell ovarian carcinomas [10], but not in ccRCC [11].
The KRAS mutation detected in our patient occurs fre-
quently in lung adenocarcinomas and is associated with
smoking. Here we assume that this represents the driver
mutation of the tumor of our patient.
4. Conclusion
To our knowledge, this case is the ﬁrst report of molecular
aberrations in clear cell adenocarcinoma of the lung.
Although this subtype of adenocarcinoma of the lung
K. Stopsack et al.8presents with striking histological features, the driver
mutation corresponds to the major histotype.
5. Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal on request.
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